Jaguar Health, Inc. (JAGX)

4.6100 +0.2500 (+5.74%) As of 12:36PM EDT. Market open.

Jaguar Health, Inc.

200 Pine Street
Suite 400
San Francisco, CA 94104
United States
415 371 8300
https://jaguar.health

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 49

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Lisa A. Conte	Founder, CEO, President & Director	610.66k	N/A	1959
Dr. Pravin R. Chaturvedi Ph.D.	Chief Scientific Officer & Chair of Scientific Advisory Board	517.91k	N/A	1963
Dr. Steven R. King Ph.D.	Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary	406.4k	N/A	1958
Ms. Carol R. Lizak M.B.A.	Chief Financial Officer	N/A	N/A	1964
Mr. Peter Hodge	Senior Director of Investor Relations, Business Development & Special Events	N/A	N/A	N/A
Dr. Karen J. Brunke Ph.D.	Executive VP of Corporate & Business Development	N/A	N/A	1953
Mr. David Sesin Ph.D.	Chief Manufacturing Officer	N/A	N/A	N/A
Mr. Ian H. Wendt M.B.A.	Chief Commercial Officer	441.31k	N/A	1968
Dr. Massimo Radaelli M.B.A., Ph.D.	President of Jaguar International	N/A	N/A	1958
Ms. Catherine Miller Collis	Senior Vice President of Growth Strategy	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Corporate governance

Jaguar Health, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.